Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.63 |
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13374080 | 1.00 | PPARG (0.63) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13374081 | 1.00 | PPARG (0.63) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13523120 | 0.96 | PPARG (0.60) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13523108 | 0.94 | PPARG (0.56) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13523102 | 0.92 | PPARG (0.54) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13523096 | 0.91 | PPARG (0.53) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13523174 | 0.91 | PPARG (0.51) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13522956 | 0.89 | PPARG (0.54) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL13523114 | 0.89 | PPARG (0.51) | PPARGPPARAALDH1A1KDM4EHPGD | |
| SCHEMBL16348349 | 0.89 | PPARG (0.58) | PPARGPPARAALDH1A1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078421-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045361-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PPARG 409/4885PPARA 123/4885ALDH1A1 3386/4885 |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PPARG 409/4885PPARA 123/4885ALDH1A1 3386/4885 |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885ALDH1A1 1316/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | PPARG 409/4885PPARA 123/4885ALDH1A1 3386/4885 |
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PPARG 409/4885PPARA 123/4885ALDH1A1 3386/4885 |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885ALDH1A1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.